Akbar Dorgalaleh

Dr. Akbar Dorgalaleh

Iran University of Medical Sciences
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
Emmanuel J FavaloroEmmanuel J Favaloro
Emmanuel J Favaloro
MBMehran Bahraini
Mehran Bahraini
FRFariba Rad
Fariba Rad
The prothrombin time (PT) represents the most commonly used coagulation test in clinical laboratories. The PT is mathematically converted to the international normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K antagonists such as warfarin in order to provide test results that are adjusted for thromboplastin and instrument used. The INR is created using two major PT ‘correction factors’, namely the mean normal PT (MNPT) and the international sensitivity index (ISI). Manufacturers of reagents and coagulometers have made some efforts to harmonizing INRs, for example, by tailoring reagents to specific coagulometers and provide associated ISI values. Thus, two types of ISIs may be generated, with one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer‐specific ISI values. Although these play a crucial role in improving INR results between laboratories, these laboratories reported INR values are known to still differ, even when laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI values for a specific thromboplastin can vary among different models of coagulometers from a manufacturer using the same method for clot identification. All these factors can be sources of error for INR reporting, which in turn can significantly affect patient management. In this narrative review, we provide some guidance to appropriate ISI verification/validation, which may help decrease the variability in cross laboratory reporting of INRs.

1 November 2016 in Blood Reviews
Verified
Journal Article
Closed access
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
JRJamal Rashidpanah
Jamal Rashidpanah

18 September 2014 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MNMajid Naderi
Majid Naderi
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
SAShaban Alizadeh
Shaban Alizadeh
STShadi Tabibian
Shadi Tabibian
SHSoudabeh Hosseini
Soudabeh Hosseini
TBTaregh Bamedi
Taregh Bamedi

23 May 2019 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
STShadi Tabibian
Shadi Tabibian
YSYavar Shiravand
Yavar Shiravand
MSMahmood Shams
Mahmood Shams
MSMajid Safa
Majid Safa
MGMohammad Saeed Gholami
Mohammad Saeed Gholami
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future.

23 January 2015 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
MHMaryam Sadat Hosseini
Maryam Sadat Hosseini
SHSoudabeh Hosseini
Soudabeh Hosseini
STShadi Tabibian
Shadi Tabibian
PEPeyman Eshghi
Peyman Eshghi
SAShaban Alizadeh
Shaban Alizadeh
Factor XIII deficiency (FXIIID) is a rare bleeding disorder with an estimated prevalence of 1 in 2-million population worldwide. In Iran, a Middle Eastern country with a high rate of consanguineous marriages, there are approximately 473 patients afflicted with FXIIID. An approximately 12-fold higher prevalence of FXIIID is estimated in Iran in comparison with overall worldwide frequency. In this study, we have undertaken a comprehensive review on different aspects of FXIIID in the Iranian population. The distribution of this disease in different regions of Iran reveals that Sistan and Baluchestan Province has not only the highest number of patients with FXIIID in Iran but the highest global incidence of this condition. Among Iranian patients, umbilical cord bleeding, hematoma, and prolonged wound bleeding are the most frequent clinical manifestations. There are several disease causing mutations in Iranian patients with FXIIID, with Trp187Arg being the most common mutation in FXIIID in Iran. Traditionally, the management of FXIIID in Iran was only based on administration of fresh frozen plasma or cryoprecipitate, until 2009 when FXIII concentrate became available for patient management. Various studies have evaluated the efficacy and safety of prophylactic regimens in different situations with valuable findings. Although the focus of this study is on Iran, it offers considerable insight into FXIIID, which can be applied more extensively to improve the management and quality of life in all affected patients.

22 December 2015 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
MNMajid Naderi
Majid Naderi
MSMorteza of Shamsizadeh
Morteza of Shamsizadeh